WO2002046454A2 - Diagnose von mit angiogenese assoziierten krankheiten durch bestimmung der methylierung von mit angiogenese assoziierten genen - Google Patents
Diagnose von mit angiogenese assoziierten krankheiten durch bestimmung der methylierung von mit angiogenese assoziierten genen Download PDFInfo
- Publication number
- WO2002046454A2 WO2002046454A2 PCT/EP2001/014320 EP0114320W WO0246454A2 WO 2002046454 A2 WO2002046454 A2 WO 2002046454A2 EP 0114320 W EP0114320 W EP 0114320W WO 0246454 A2 WO0246454 A2 WO 0246454A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- cfl
- dna
- oligonucleotide
- oligomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to nucleic acids, oligonucleotides, PNA oligomers and a method for the diagnosis and / or therapy of diseases which are related to the genetic and / or epigenetic parameters of genes associated with angiogenesis and in particular their methylation status.
- Angiogenesis describes the process of forming new blood vessels. This process, also known as neovascularization, normally takes place during embryogenesis and placental development, but also in the adult organism and during wound healing. Stimulation by one or more known growth factors initiates angiogenesis, but other, as yet unidentified, factors may also be involved. Angiogenesis is controlled by the Balance between stimulators and inhibitors and is suppressed under normal physiological conditions. A shift in this balance plays a crucial role in the development of a variety of diseases, the differences of which
- Pathogenic conditions with which angiogenesis is associated include, for example, eye diseases, proliferative retinopathy, neovascular glaucoma, solid tumors and diseases related to tissue inflammation such as rheumatoid arthritis (Moses MA, Langer R. Inhibitors of angiogenesis. Biotechnology ( NY) 1991 Jul; 9 (7): 630-4): Further diabetic retinopathy, macular degeneration due to neovascularization, psoriasis or atherosclerosis (Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.Adv Cancer Res. 2000; 79: 1-38), ulcerative bowel catarrh (Thorn M,
- angiogenesis in such diverse diseases as cancer, eye diseases and inflammatory diseases has led to the development of methods that are specifically concerned with the inhibition of angiogenesis.
- methods that are specifically concerned with the inhibition of angiogenesis.
- cancer patients such methods have a significant advantage over conventional methods, such as Chemotherapy with its massive side effects, which sometimes result in unacceptable morbidity or lead to the death of the patient.
- Chemotherapy with its massive side effects, which sometimes result in unacceptable morbidity or lead to the death of the patient.
- these undesirable side effects associated with cancer therapies often limit the treatment that could help a patient.
- 5-methylcytosine positions cannot be identified by sequencing because 5-methylcytosine has the same base pairing behavior as cytosine.
- the epigenetic information which the 5-methylcytosines carry is completely lost.
- the bisulfite technique has so far been used with a few exceptions (e.g. Zeschnigk M, Lieh C, Buiting K, Doerfler W, Horsthemke B. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. Eur J Hum Geet. 1997 Mar-Apr; 5 (2): 94-8) only used in research. However, short, specific pieces of a known gene are always amplified after bisulfite treatment and either completely sequenced (Olek A, Walter J. The pre-implantation ontogeny of the H19 methylation i print. Nat Genet.
- Fluorescence-labeled probes have been used in many cases for scanning an immobilized DNA array.
- the simple attachment of Cy3 and Cy5 dyes to the 5 'OH of the respective probe is particularly suitable for fluorescent labels.
- the fluorescence of the hybridized probes is detected, for example, using a confocal microscope.
- the dyes Cy3 and Cy5, among many others, are commercially available.
- Matrix-assisted laser desorption / ionization mass spectrometry is a very powerful development for the analysis of biomolecules (Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular asses exceeding 10,000 daltons. Anal Chem. 1988 Oct 15; 60 (20): 2299-301).
- An analyte is embedded in a light-absorbing matrix. The matrix is vaporized by a short laser pulse and the analyte molecule is thus transported unfragmented into the gas phase. The ionization of the analyte is achieved by collisions with matrix molecules.
- An applied voltage accelerates the ions into a field-free flight tube. Due to their different masses, ions are accelerated to different extents. Smaller ions reach the detector earlier than larger ones.
- MALDI-TOF spectrometry is excellently suited for the analysis of peptides and proteins.
- the analysis of nucleic acids is somewhat more difficult (Gut IG, Beck S. DNA and Matrix Assisted Laser Desorption Ionization Mass Spectrometry. Current Innovations and Future Trends. 1995, 1; 147-57).
- the sensitivity for nucleic acids is about 100 times worse than for peptides and decreases disproportionately with increasing fragment size. For nucleic acids that have a backbone that is often negatively charged, the ionization process through the matrix is much more inefficient.
- MALDI-TOF spectrometry the choice of the matrix plays an eminently important role.
- the base sequence of the oligomers comprises at least one CpG dinucleotide.
- the probes can also be in the form of a PNA (Peptide Nucleic Acid), which has particularly preferred pairing properties.
- PNA Peptide Nucleic Acid
- Particularly preferred are oligonucleotides according to the invention in which the cytosine of the CpG dinucleotide is the 5th to 9th nucleotide from the 5 'end of the 13 r ⁇ er, in the case of PNA oligomers it is preferred that the cytosine of the CpG dinucleotide is the 4th - 6th nucleotide from the 5 'end of the 9 mer.
- the oligomers according to the invention are normally used in so-called sets which contain one of the sequences of Seq. ID No.l to Seq. ID No.208 and to their complementary sequences and / or oligonucleotide and / or PNA oligomers according to Table 1 comprise at least one oligomer.
- a set is preferred which comprises at least one oligomer for each of the CpG dinucleotides from one of Seq ID No. 1 to Seq ID No.208 and to their complementary sequences and / or oligonucleotide and / or PNA oligomers according to Table 1 ,
- the invention provides a set of at least two oligonucleotides which, as so-called primer oligonucleotides, for the amplification of DNA sequences of one of the Seq. ID No.l to Seq. ID No.208 and their complementary sequences and / or oligonucleotide and / or PNA oligomers according to Table 1 or sections thereof can be used.
- At least one oligonucleotide is bound to a solid phase.
- the present invention further relates to a set of at least 10 n (oligonucleotides and / or PNA- Oligomers), which are used to detect the cytosine methylation state in chemically pretreated genomic DNA (Seq. ID No. 1 to Seq. ID No.208 and their complementary sequences and / or oligonucleotide and / or PNA oligomers according to Table 1) , With these probes the diagnosis and / or therapy of genetic and epigenetic parameters of genes associated with angiogenesis is possible.
- the set of oligomers can also be used to detect single nucleotide polymorphisms (SNPs) in the chemically pretreated DNA of genes associated with angiogenesis according to one of the Seq. ID No.l to Seq. ID No.208 and their complementary sequences and / or oligonucleotide and / or PNA oligomers according to Table 1 can be used.
- SNPs single nucleotide polymorphisms
- an arrangement made of different oligonucleotides and / or PNA oligomers (a so-called "array") provided by the invention is also bound to a solid phase.
- This array of different oligonucleotide and / or PNA oligomer sequences can be characterized in that it is arranged on the solid phase in the form of a rectangular or hexagonal grid.
- the solid phase surface preferably consists of silicon, glass, polystyrene, aluminum, steel, iron, copper, nickel, silver or gold.
- nitrocellulose and plastics such as nylon are also possible, which can be in the form of spheres or as resin matrices.
- the invention therefore furthermore relates to a method for producing an array fixed on a carrier material for analysis in connection with diseases associated with angiogenesis, in which at least one oligomer according to the invention is coupled to a solid phase.
- Process for the production of such arrays co CO t to P »P> c ⁇ o C ⁇ o C ⁇ o C ⁇ o C ⁇
- P- P- DJ ⁇ 0 ⁇ d P rt P- 3 P Hl tr ⁇ P ⁇ ⁇ P- a tr P- _- ⁇ P ⁇
- the fragments generated can have a single positive or negative net charge for better detectability in the mass spectrometer.
- the aforementioned method is preferably used to determine genetic and / or epigenetic parameters of genes associated with angiogenesis.
- the oligomers or arrays thereof according to the invention and a kit according to the invention are to be used for the diagnosis and / or therapy of diseases associated with angiogenesis by analyzing methylation patterns of genes associated with angiogenesis. According to the invention, the use of the method for diagnosis and / or therapy of important genetic and / or epigenetic parameters within genes associated with angiogenesis is preferred.
- the method according to the invention serves, for example, to diagnose and / or treat eye diseases, proliferative retinopathy, neovascular glaucoma, solid tumors, tissue inflammation, rheumatic arthritis, diabetic retinopathy, acular degeneration due to neovascularization, psoriasis, atherosclerosis, inflammatory bowel disease Intestinal catarrh, Morbus Crohn and cancer.
- the nucleic acids of Seq. ID No.l to Seq. ID No.208 and their complementary sequences and / or oligonucleotide and / or PNA oligomers according to Table 1 can be used for the diagnosis and / or therapy of genetic and / or epigenetic parameters of genes associated with angiogenesis.
- the present invention further relates to a method for producing a diagnostic and / or therapeutic for the diagnosis and / or therapy of diseases associated with angiogenesis by analyzing methylation patterns of genes associated with angiogenesis, the diagnostic and / or therapeutic agent being characterized thereby that at least one nucleic acid, according to the present invention, is optionally used together with suitable additives and auxiliaries for its production.
- the present invention further relates to a diagnostic and / or therapeutic agent for diseases associated with angiogenesis by analyzing methylation patterns of genes associated with angiogenesis, which comprises at least one nucleic acid according to the invention, optionally together with suitable additives and adjuvants.
- the present invention further relates to the diagnosis and / or prognosis of adverse events for patients or individuals, in which the significant genetic and / or epigenetic parameters obtained by the invention are compared within genes associated with angiogenesis with another set of genetic and / or epigenetic parameters can and the differences thus obtained serve as the basis for a diagnosis and / or prognosis of adverse events for patients or individuals.
- hybridization in the sense of the present invention is to be understood as binding with the formation of a duplex structure of an oligonucleotide to a completely complementary sequence in the sense of the Watson-Crick base pairings in the sample DNA.
- stringent hybridization conditions such conditions are too understand, in which a hybridization at 60 ° C in 2.5 x SSC buffer, followed by several washing steps at 37 ° C in a lower buffer concentration and remains stable.
- the term “functional variants” denotes all DNA sequences that are complementary to a DNA sequence that hybridize with the reference sequence under stringent conditions and have an activity similar to the corresponding polypeptide according to the invention.
- Genetic parameters in the sense of this invention are mutations and polymorphisms of genes associated with angiogenesis and sequences which are also required for its regulation.
- insertions, deletions, point mutations, inversions and polymorphisms and particularly preferably SNPs (single nucleotide polymorphisms) are to be referred to as mutations.
- Polymorphisms can also be insertions, deletions or inversions.
- Epigenetic parameters in the sense of this invention are, in particular, cytosine methylations and further chemical modifications of DNA bases of genes associated with angiogenesis and sequences which are also required for their regulation. Further epigenetic parameters are, for example, the acetylation of histones, which, however, cannot be analyzed directly with the method described, but in turn correlates with DNA methylation.
- Sequences with odd sequence numbers (e.g. Seq. ID No. 1, 3, 5, 7) each show different sequences of the chemically pretreated genomic DNAs from genes associated with angiogenesis.
- Sequences with even sequence numbers each show the sequences that are complementary to the different sequences (eg the sequence that is complementary to Seq. ID No. 1 is Seq. ID No.2 , to Seq. ID No.3 the complementary sequence Seq. ID No.4 etc.) of the chemically pretreated genomic DNAs of genes associated with angiogenesis.
- the following example relates to a fragment of a gene associated with angiogenesis, here TIMP-3, in which a particular CG position is examined for its methylation status.
- Example 1 Performing the methylation analysis in the TIMP-3 gene associated with angiogenesis
- the following example relates to a fragment of the metalloproteinase-3 (TIMP-3) gene in which a specific CG position is to be examined for methylation.
- TIMP-3 metalloproteinase-3
- a genomic sequence is treated using bisulfite (hydrogen sulfite, disulfite) in such a way that all cytosines not ethylated at the 5-position of the base are modified in such a way that a base which is different with regard to the base pairing behavior is formed, while the 5-position methylated cyto- remain unchanged.
- bisulfite in the concentration range between 0.1 M and 6 M is used for the reaction, an addition takes place at the unmethylated cytosine bases.
- a denaturing reagent or solvent and a radical scavenger must be present. Subsequent alkaline hydrolysis then leads to the conversion of unmethylated cytosine nucleobases into uracil.
- the treated DNA sample is diluted with water or an aqueous solution. Desulphonation of the DNA (10-30 min, 90-100 ° C.) at alkaline pH is then preferably carried out.
- the DNA sample is amplified in a polymerase chain reaction, preferably with a heat-resistant DNA
- cytosines of the TIMP-3 gene are examined.
- a defined fragment with a length of 401 bp is amplified with the specific prime oligonucleotides AGAGAAATTGGAGGGGTAGT and CCCTCAAACCAATAACAAAA.
- This amplificate serves as a sample which hybridizes to an oligonucleotide previously bound to a solid phase to form a duplex structure, for example GGATTTAGCGGTAAGTAT, the cytosine to be detected being at position 223 of the amplificate.
- the detection of the hybridization product is based on Cy3 and Cy5 fluorescence-labeled primer oligonucleotides that were used for the amplification. Only if there is a methylated cytosine in the bisulfite-treated DNA at this point will there be a hybridization reaction of the amplified DNA with the
- Oligonucleotide The methylation status of the cytosine to be investigated thus decides on the hybridization product. ⁇ t tv> P 1 P 1 o c ⁇ o c ⁇ o C ⁇
- DJ P- 0 P- 0 d I ⁇ j 0 • s 0 ET ET ⁇ P- P- d ⁇ P rt CO O ⁇ > P d
- Example 3 Performing the methylation analysis in the CDKN2A gene
- a genomic sequence is treated using bisulfite (hydrogen sulfite, disulfite) in such a way that all cytosines that are not methylated at the 5-position of the base are changed in such a way that a base which is different with regard to the base pairing behavior is formed, while the base in FIG -Position methylated cytosines remain unchanged.
- bisulfite hydrogen sulfite, disulfite
- an addition takes place at the unmethylated cytosine bases.
- a denaturing reagent or solvent and a radical scavenger must be present. Subsequent alkaline hydrolysis then leads to the conversion of unmethylated cytosine
- Nucleobases in uracil This converted DNA is used to detect methylated cytosines.
- the treated DNA sample is diluted with water or an aqueous solution. Desulfonation of the DNA is then preferably carried out.
- the third process step the treated DNA sample is diluted with water or an aqueous solution. Desulfonation of the DNA is then preferably carried out.
- the DNA sample is amplified in a polymerase chain reaction, preferably with a heat-resistant DNA polymerase.
- the PCR reactions were carried out in a thermal cycler (Eppendorf GmbH). 10 ng DNA, O.O ⁇ M from each primer oligonucleotide 1, 6mM dNTPs and one unit of HotstarTaq were used for a 25 ⁇ l mixture. The other conditions were chosen according to the manufacturer's instructions.
- denaturation was first carried out for 15 minutes at 96 ° C, then 40 cycles (60 seconds at 96 ° C, 45 seconds at 55 ° C and 75 seconds at 65 ° C) and a final elongation of 10 minutes at 72 ° C. The presence of the PCR products was checked on agarose gels.
- DJ o 3 ⁇ 1 DJ rt ⁇ rt o Pi K 0 ⁇ H ⁇ ⁇ DJ Pl and others H 0 ⁇ o and others 0 ⁇ 0 rt ⁇ 0 P- CO P- CL c ⁇ and others o ⁇ ET 0 Pl and others ⁇ 3 Cfl ⁇ 0 1 P rt o P- rt P- • 1 O 1 ⁇ ⁇ 0 ⁇
- the first (the left in Figure 1 and 2) contains 26 samples of both sexes, the second also contains 26 samples (in Figures 1 and 2 on the right side).
- the p-value weighted methylation shows a clear distinction between the two groups, 12 CpG positions (red or gray color shading) of 11 different genes are significantly differentiated (corrected p-value ⁇ 0.05) between the two groups.
- the cross-validated accuracy of the classification, by SVM (support vector machine) (F. Model, P. Adorjan, A. 0- lek, C. Piepenbrock, Feature selection for DNA methylation based cancer classification. Bioinformatics. 2001 Jun; 17 Suppl 1: S157-64) is calculated as 77.0% with a standard deviation of 4.4%.
- the CDKN2A gene which is represented by the gene identification number 2035, was examined as part of a larger study.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002217091A AU2002217091A1 (en) | 2000-12-06 | 2001-12-06 | Diagnosis of diseases associated with angiogenesis by determining the methylation of genes associated with angiogenesis |
EP01999661A EP1402059A2 (de) | 2000-12-06 | 2001-12-06 | Diagnose von mit angiogenese assoziierten krankheiten durch bestimmung der methylierung von mit angiogenese assoziierten genen |
US10/433,793 US20040142334A1 (en) | 2000-12-06 | 2001-12-06 | Diagnosis of diseases associated with angiogenesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10061338.1 | 2000-12-06 | ||
DE10061338A DE10061338A1 (de) | 2000-12-06 | 2000-12-06 | Diagnose von mit Angiogenese assoziierten Krankheiten |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002046454A2 true WO2002046454A2 (de) | 2002-06-13 |
WO2002046454A3 WO2002046454A3 (de) | 2003-12-24 |
Family
ID=7666455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/014320 WO2002046454A2 (de) | 2000-12-06 | 2001-12-06 | Diagnose von mit angiogenese assoziierten krankheiten durch bestimmung der methylierung von mit angiogenese assoziierten genen |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040142334A1 (de) |
EP (1) | EP1402059A2 (de) |
AU (1) | AU2002217091A1 (de) |
DE (1) | DE10061338A1 (de) |
WO (1) | WO2002046454A2 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10245779A1 (de) * | 2002-10-01 | 2004-04-29 | Epigenomics Ag | Verfahren und Nukleinsäuren für die verbesserte Behandlung von proliferativen Erkrankungen von Brustzellen |
WO2006111586A2 (es) * | 2005-04-20 | 2006-10-26 | Proyecto De Biomedicina Cima, S.L. | Procedimiento para la determinación in vitro del grado de metilación del promotor de line-1 |
WO2017214397A1 (en) * | 2016-06-08 | 2017-12-14 | University Of Iowa Research Foundation | Compositions and methods for detecting predisposition to cardiovascular disease |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7617163B2 (en) * | 1998-05-01 | 2009-11-10 | Health Discovery Corporation | Kernels and kernel methods for spectral data |
WO2006088978A1 (en) | 2005-02-16 | 2006-08-24 | Epigenomics, Inc. | Method for determining the methylation pattern of a polynucleic acid |
US7932027B2 (en) | 2005-02-16 | 2011-04-26 | Epigenomics Ag | Method for determining the methylation pattern of a polynucleic acid |
PT1871912E (pt) | 2005-04-15 | 2012-05-25 | Epigenomics Ag | Método para determinar metilação de adn em amostras de sangue ou urina |
US8084734B2 (en) * | 2006-05-26 | 2011-12-27 | The George Washington University | Laser desorption ionization and peptide sequencing on laser induced silicon microcolumn arrays |
CN101680038A (zh) * | 2007-04-13 | 2010-03-24 | 百时美施贵宝公司 | 用于确定对血管内皮生长因子受体2调节剂的敏感性的生物标志物和方法 |
US8110796B2 (en) | 2009-01-17 | 2012-02-07 | The George Washington University | Nanophotonic production, modulation and switching of ions by silicon microcolumn arrays |
US9490113B2 (en) * | 2009-04-07 | 2016-11-08 | The George Washington University | Tailored nanopost arrays (NAPA) for laser desorption ionization in mass spectrometry |
AU2012209185B2 (en) * | 2011-01-25 | 2016-06-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing and treating age-related macular degeneration |
WO2013033627A2 (en) * | 2011-09-01 | 2013-03-07 | The Regents Of The University Of California | Diagnosis and treatment of arthritis using epigenetics |
WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744305A (en) * | 1989-06-07 | 1998-04-28 | Affymetrix, Inc. | Arrays of materials attached to a substrate |
WO1999028498A2 (de) * | 1997-11-27 | 1999-06-10 | Epigenomics Gmbh | Verfahren zur herstellung komplexer dna-methylierungs-fingerabdrücke |
WO1999029898A2 (de) * | 1997-12-05 | 1999-06-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zur identifikation von nucleinsäuren durch matrix-assistierte laser desorptions/ionisations massenspektrometrie |
DE19905082C1 (de) * | 1999-01-29 | 2000-05-18 | Epigenomics Gmbh | Verfahren zur Identifikation von Cytosin-Methylierungsmustern in genomischen DNA-Proben |
WO2002000928A2 (de) * | 2000-06-30 | 2002-01-03 | Epigenomics Ag | Diagnose von mit dem immunsystem assoziierten krankheiten durch bestimmung der cytosin-methylierung |
WO2002018632A2 (de) * | 2000-09-01 | 2002-03-07 | Epigenomics Ag | Verfahren zur bestimmung des methylierungsgrades von bestimmten cytosinen in genomischer dna im sequenzkontext 5'-cpg-3' |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251594B1 (en) * | 1997-06-09 | 2001-06-26 | Usc/Norris Comprehensive Cancer Ctr. | Cancer diagnostic method based upon DNA methylation differences |
WO1999064626A2 (en) * | 1998-06-06 | 1999-12-16 | Genostic Pharma Limited | Probes used for genetic profiling |
WO1999064627A2 (en) * | 1998-06-06 | 1999-12-16 | Genostic Pharma Limited | Probes used for genetic profiling |
-
2000
- 2000-12-06 DE DE10061338A patent/DE10061338A1/de not_active Ceased
-
2001
- 2001-12-06 US US10/433,793 patent/US20040142334A1/en not_active Abandoned
- 2001-12-06 WO PCT/EP2001/014320 patent/WO2002046454A2/de not_active Application Discontinuation
- 2001-12-06 EP EP01999661A patent/EP1402059A2/de not_active Withdrawn
- 2001-12-06 AU AU2002217091A patent/AU2002217091A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744305A (en) * | 1989-06-07 | 1998-04-28 | Affymetrix, Inc. | Arrays of materials attached to a substrate |
WO1999028498A2 (de) * | 1997-11-27 | 1999-06-10 | Epigenomics Gmbh | Verfahren zur herstellung komplexer dna-methylierungs-fingerabdrücke |
WO1999029898A2 (de) * | 1997-12-05 | 1999-06-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zur identifikation von nucleinsäuren durch matrix-assistierte laser desorptions/ionisations massenspektrometrie |
DE19905082C1 (de) * | 1999-01-29 | 2000-05-18 | Epigenomics Gmbh | Verfahren zur Identifikation von Cytosin-Methylierungsmustern in genomischen DNA-Proben |
WO2002000928A2 (de) * | 2000-06-30 | 2002-01-03 | Epigenomics Ag | Diagnose von mit dem immunsystem assoziierten krankheiten durch bestimmung der cytosin-methylierung |
WO2002018632A2 (de) * | 2000-09-01 | 2002-03-07 | Epigenomics Ag | Verfahren zur bestimmung des methylierungsgrades von bestimmten cytosinen in genomischer dna im sequenzkontext 5'-cpg-3' |
Non-Patent Citations (12)
Title |
---|
CODY D T ET AL: "Differential DNA methylation of the p16 INK4A/CDKN2A promoter in human oral cancer cells and normal human oral keratinocytes" ORAL ONCOLOGY, ELSEVIER SCIENCE, OXFORD, GB, Bd. 35, Nr. 5, September 1999 (1999-09), Seiten 516-522, XP004286629 ISSN: 1368-8375 * |
CUI J ET AL: "HYPERMETHYLATION OF THE CAVEOLIN-1 GENE PROMOTER IN PROSTATE CANCER" PROSTATE, WILEY-LISS, NEW YORK, NY, US, Bd. 46, Nr. 3, 15. Februar 2001 (2001-02-15), Seiten 249-256, XP001064091 ISSN: 0270-4137 * |
DATABASE GENBANK [Online] NCBI; 2. Juni 1999 (1999-06-02) FRA ET AL.: "Homo sapiens caveolin-2 gene intron 1" retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV Database accession no. AJ011300 XP002225347 -& FRA ET AL.: "Human Caveolin-1 and Caveolin-2 are closely linked genes colocalized with WI-5336 in a region of 7q31 frequently deleted in tumors." GENOMICS, Bd. 56, 1999, Seiten 355-356, XP002225345 * |
DATABASE GENBANK [Online] NCBI; 9. Dezember 1997 (1997-12-09) SCHERER: "Homo sapiens caveolin-2 mRNA" retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV Database accession no. AF035752 XP002225348 * |
ENGELMAN J A ET AL: "Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1) - Methylation of a CpG island in the 5' promoter region of the caveolin-1 gene in human breast cancer cell lines" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, Bd. 448, Nr. 2-3, 9. April 1999 (1999-04-09), Seiten 221-230, XP004259501 ISSN: 0014-5793 -& DATABASE EMBL [Online] EBI; 16. Dezember 1999 (1999-12-16) LISANTI M.P.: "Homo sapiens caveolin-1/-2 locus" retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AJ133269 XP002225171 * |
FRA A M ET AL: "Genomic organization and transcriptional analysis of the human genes coding for caveolin-1 and caveolin-2" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, Bd. 243, Nr. 1-2, Februar 2000 (2000-02), Seiten 75-83, XP004187676 ISSN: 0378-1119 -& DATABASE GENBANK [Online] NCBI; 3. März 2000 (2000-03-03) FRA ET AL.: "Homo sapiens partial CAV2 gene for caveolin-2 protein and promoter" retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV Database accession no. AJ242718 XP002225346 * |
GRIFFIOEN A W ET AL: "Endothelial CD44 is involved in tumor angiogenesis." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, Bd. 38, 1997, Seite 290 XP001121742 Eighty-eighth Annual Meeting of the American Association for Cancer Research;San Diego, California, USA; April 12-16, 1997, 1997 ISSN: 0197-016X * |
GRIFFONI CRISTIANA ET AL: "Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Bd. 276, Nr. 2, 24. September 2000 (2000-09-24), Seiten 756-761, XP002225168 ISSN: 0006-291X * |
HARADA HIRONOBU ET AL: "Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas." CANCER RESEARCH, Bd. 59, Nr. 15, 1. August 1999 (1999-08-01), Seiten 3783-3789, XP002225170 ISSN: 0008-5472 * |
NIEMEYER C M ET AL: "DNA MICROARRAYS**" ANGEWANDTE CHEMIE, VCH VERLAGSGESELLSCHAFT, WEINHEIM, DE, Bd. 38, Nr. 19, 1999, Seiten 3039-3043, XP000961724 ISSN: 0044-8249 * |
REIN ET AL: "Identifying 5-methylcytosine and related modifications in DNA genomes" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, Bd. 26, Nr. 10, 1998, Seiten 2255-2264, XP002143106 ISSN: 0305-1048 in der Anmeldung erwähnt * |
VERKAIK NICOLE S ET AL: "Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region." LABORATORY INVESTIGATION, Bd. 80, Nr. 8, August 2000 (2000-08), Seiten 1291-1298, XP002225169 ISSN: 0023-6837 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10245779A1 (de) * | 2002-10-01 | 2004-04-29 | Epigenomics Ag | Verfahren und Nukleinsäuren für die verbesserte Behandlung von proliferativen Erkrankungen von Brustzellen |
WO2006111586A2 (es) * | 2005-04-20 | 2006-10-26 | Proyecto De Biomedicina Cima, S.L. | Procedimiento para la determinación in vitro del grado de metilación del promotor de line-1 |
WO2006111586A3 (es) * | 2005-04-20 | 2006-12-14 | Proyecto Biomedicina Cima Sl | Procedimiento para la determinación in vitro del grado de metilación del promotor de line-1 |
WO2017214397A1 (en) * | 2016-06-08 | 2017-12-14 | University Of Iowa Research Foundation | Compositions and methods for detecting predisposition to cardiovascular disease |
US11414704B2 (en) | 2016-06-08 | 2022-08-16 | University Of Iowa Research Foundation | Compositions and methods for detecting predisposition to cardiovascular disease |
AU2017277666B2 (en) * | 2016-06-08 | 2023-07-27 | University Of Iowa Research Foundation | Compositions and methods for detecting predisposition to cardiovascular disease |
Also Published As
Publication number | Publication date |
---|---|
DE10061338A1 (de) | 2002-06-20 |
WO2002046454A3 (de) | 2003-12-24 |
US20040142334A1 (en) | 2004-07-22 |
AU2002217091A1 (en) | 2002-06-18 |
EP1402059A2 (de) | 2004-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10130800B4 (de) | Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität | |
DE60126593T2 (de) | Diagnose von mit apoptose assoziierten erkrankungen mittels ermittlung des methylierungszustandes von apoptose-assozierten genen | |
EP1432828B1 (de) | Verfahren zum nachweis von cytosin-methylierung in cpg-inseln | |
EP1294951A2 (de) | Diagnose von mit dem immunsystem assoziierten krankheiten | |
WO2002072880A2 (de) | Verfahren zum nachweis von cytosin-methylierungsmustern mit hoher sensitivität | |
EP1463841A2 (de) | Verfahren zum nachweis von cytosin-methylierungsmustern durch exponentielle ligation hybridisierter sondenoligonukleotide (mla) | |
WO2002046454A2 (de) | Diagnose von mit angiogenese assoziierten krankheiten durch bestimmung der methylierung von mit angiogenese assoziierten genen | |
DE10154317B4 (de) | Verfahren zum Nachweis von Cytosin-Methylierungen in immobilisierten DNA Proben | |
WO2003038120A2 (de) | Verfahren zur analyse genomischer methylierungsmuster | |
DE10132212A1 (de) | Verfahren zum Nachweis von Cytosin-Methylierung durch vergleichende Analyse der Einzelstränge von Amplifikaten | |
WO2002036814A2 (de) | Diagnose von mit cdk4 assoziierten krankheiten durch bestimmung des methylierungszustandes des cdk4 | |
EP1339873B1 (de) | Diagnose von mit humos assoziierten krankheiten | |
DE10304219B3 (de) | Verfahren zum Nachweis von Cytosin-Methylierungsmustern mit hoher Sensitivität | |
WO2002012554A2 (de) | Diagnose von mit cd24 assoziierten krankheiten | |
EP1432827B1 (de) | Verfahren zum nachweis von dna-methylierung mittels markierten s-adenosylmethioninanaloga | |
EP1534864A2 (de) | Verfahren zum nachweis von nukleinsäuresequenzen mittels spaltbarer sondenmoleküle | |
DE20121969U1 (de) | Nukleinsäuren für die Diagnose von mit DNA Reparatur assoziierten Krankheiten | |
DE20121965U1 (de) | Nukleinsäuren für die Diagnose von mit DNA Addukten assoziierten Krankheiten | |
DE20121967U1 (de) | Nukleinsäuren für die Diagnose von Verhaltensstörungen, neurologischen Erkrankungen und Krebs | |
DE20121961U1 (de) | Nukleinsäuren für die Diagnose von mit der Signaltransduktion assoziierten Krankheiten | |
DE20121979U1 (de) | Nukleinsäuren für die Diagnose von mit der Zellsignalisierung assoziierten Krankheiten | |
DE20121977U1 (de) | Nukleinsäuren für die Diagnose von mit Tumor-Suppressorgenen und Onkogenen assoziierten Krankheiten | |
DE20121964U1 (de) | Nukleinsäuren für die Diagnose von mit dem Metabolismus assoziierten Krankheiten | |
DE20121968U1 (de) | Nukleinsäuren für die Diagnose von mit Apoptose assoziierten Krankheiten | |
DE20121974U1 (de) | Nukleinsäuren für die Diagnose von mit DNA Replikation assoziierten Krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001999661 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002217091 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10433793 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001999661 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |